Viberzi Patent Expiration

Viberzi is a drug owned by Abbvie Inc. It is protected by 20 US drug patents filed from 2015 to 2022 out of which none have expired yet. Viberzi's patents have been open to challenges since 28 May, 2019. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 14, 2033. Details of Viberzi's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US7741356 Compounds as opioid receptor modulators
May, 2029

(4 years from now)

Active
US9115091 Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(3 years from now)

Active
US8691860 Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(3 years from now)

Active
US7786158 Compounds as opioid receptor modulators
Mar, 2025

(4 months from now)

Active
US8609709 Compounds as opioid receptor modulators
Mar, 2025

(4 months from now)

Active
US10213415 Compounds as opioid receptor modulators
Mar, 2025

(4 months from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188632 Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

Active
US9675587 Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

Active
US11229627 Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

Active
US11311516 Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

Active
US11007179 Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

Active
US11090291 Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

Active
US11160792 Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

Active
US11484527 Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

Active
US9364489 Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(3 years from now)

Active
US9789125 Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(3 years from now)

Active
US9700542 Compounds as opioid receptor modulators
Mar, 2025

(4 months from now)

Active
US9205076 Compounds as opioid receptor modulators
Mar, 2025

(4 months from now)

Active
US8344011 Compounds as opioid receptor modulators
Mar, 2025

(4 months from now)

Active
US8772325 Compounds as opioid receptor modulators
Mar, 2025

(4 months from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Viberzi's patents.

Given below is the list of recent legal activities going on the following patents of Viberzi.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 13 Jun, 2024 US8344011
Payment of Maintenance Fee, 8th Year, Large Entity 10 May, 2023 US9205076
Payment of Maintenance Fee, 8th Year, Large Entity 11 Jan, 2023 US9115091
Patent Issue Date Used in PTA Calculation 01 Nov, 2022 US11484527
Recordation of Patent Grant Mailed 01 Nov, 2022 US11484527
Email Notification 13 Oct, 2022 US11484527
Issue Notification Mailed 12 Oct, 2022 US11484527
Dispatch to FDC 28 Sep, 2022 US11484527
Application Is Considered Ready for Issue 28 Sep, 2022 US11484527
Issue Fee Payment Verified 27 Sep, 2022 US11484527


FDA has granted several exclusivities to Viberzi. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Viberzi, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Viberzi.

Exclusivity Information

Viberzi holds 1 exclusivities. All of its exclusivities have expired in 2020. Details of Viberzi's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 27, 2020

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Viberzi's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Viberzi's generic, the next section provides detailed information on ongoing and past EP oppositions related to Viberzi patents.

Viberzi's Oppositions Filed in EPO

Viberzi has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 28, 2019, by Sandoz Ag. This opposition was filed on patent number EP14774006A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP14774006A May, 2019 Sandoz AG Opposition rejected


US patents provide insights into the exclusivity only within the United States, but Viberzi is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Viberzi's family patents as well as insights into ongoing legal events on those patents.

Viberzi's Family Patents

Viberzi has patent protection in a total of 40 countries. It's US patent count contributes only to 20.0% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Viberzi.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Viberzi's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 14, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Viberzi Generics:

There are no approved generic versions for Viberzi as of now.

How can I launch a generic of Viberzi before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Viberzi's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Viberzi's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Viberzi -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
75 mg and 100 mg 28 May, 2019 6 14 Mar, 2033





About Viberzi

Viberzi is a drug owned by Abbvie Inc. It is used for reducing abdominal pain and diarrhea in patients with irritable bowel syndrome with diarrhea (IBS-D) with eluxadoline. Viberzi uses Eluxadoline as an active ingredient. Viberzi was launched by Abbvie in 2015.

Approval Date:

Viberzi was approved by FDA for market use on 27 May, 2015.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Viberzi is 27 May, 2015, its NCE-1 date is estimated to be 28 May, 2019.

Active Ingredient:

Viberzi uses Eluxadoline as the active ingredient. Check out other Drugs and Companies using Eluxadoline ingredient

Treatment:

Viberzi is used for reducing abdominal pain and diarrhea in patients with irritable bowel syndrome with diarrhea (IBS-D) with eluxadoline.

Dosage:

Viberzi is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
100MG TABLET Prescription ORAL
75MG TABLET Prescription ORAL